Pegvisomant (Slovenian Wikipedia)

Analysis of information sources in references of the Wikipedia article "Pegvisomant" in Slovenian language version.

refsWebsite

Global rank Slovenian rank

13nih.gov

4^th place

8^th place

10doi.org

2^nd place

5^th place

3web.archive.org

1^st place

2^nd place

2worldcat.org

5^th place

10^th place

2semanticscholar.org

11^th place

51^st place

1termania.net

low place

34^th place

1europa.eu

68^th place

28^th place

1ohio.edu

low place

1cadth.ca

low place

cadth.ca

CEDAC Final REcommendation on Reconsideration and Reasons for Recommendation: Pegvisomant (Somavert - Pfizer Canada Inc.) (PDF) (poročilo). Canadian Agency for Drugs and Technologies in Health. 2. avgust 2006. Arhivirano iz prvotnega spletišča (PDF) dne 28. junija 2021. Pridobljeno 21. junija 2021.

doi.org

Schreiber I, Buchfelder M, Droste M, Forssmann K, Mann K, Saller B, Strasburger CJ (Januar 2007). »Treatment of acromegaly with the GH receptor antagonist pegvisomant in clinical practice: safety and efficacy evaluation from the German Pegvisomant Observational Study«. European Journal of Endocrinology. 156 (1): 75–82. doi:10.1530/eje.1.02312. PMID 17218728.
Rix, M.; Laurberg, P.; Hoejberg, A. S.; Brock-Jacobsen, B. (Avgust 2005). »Pegvisomant therapy in pituitary gigantism: successful treatment in a 12-year-old girl«. European Journal of Endocrinology. Zv. 153, št. 2. str. 195–201. doi:10.1530/eje.1.01956. ISSN 0804-4643. PMID 16061823.
Müssig, K.; Gallwitz, B.; Honegger, J.; Strasburger, C. J.; Bidlingmaier, M.; Machicao, F.; Bornemann, A.; Ranke, M. B.; Häring, H.-U. (Marec 2007). »Pegvisomant treatment in gigantism caused by a growth hormone-secreting giant pituitary adenoma«. Experimental and Clinical Endocrinology & Diabetes: Official Journal, German Society of Endocrinology [and] German Diabetes Association. Zv. 115, št. 3. str. 198–202. doi:10.1055/s-2007-956172. ISSN 0947-7349. PMID 17427111.
Freda PU, Gordon MB, Kelepouris N, Jonsson P, Koltowska-Haggstrom M, van der Lely AJ (Marec 2015). »Long-term treatment with pegvisomant as monotherapy in patients with acromegaly: experience from ACROSTUDY«. Endocrine Practice. 21 (3): 264–74. doi:10.4158/EP14330.OR. PMC 4618502. PMID 25370326.
Kopchick JJ (april 2003). »Discovery and mechanism of action of pegvisomant«. European Journal of Endocrinology. 148 Suppl 2: S21-5. doi:10.1530/eje.0.148s021. PMID 12670297.{{navedi časopis}}: Vzdrževanje CS1: samodejni prevod datuma (povezava)
Neggers SJ, Muhammad A, van der Lely AJ (2015). »Pegvisomant Treatment in Acromegaly«. Neuroendocrinology. 103 (1): 59–65. doi:10.1159/000381644. PMID 25792221. S2CID 19588354.
Feenstra J, van Aken MO, de Herder WW, Feelders RA, van der Lely AJ (Junij 2006). »Drug-induced hepatitis in an acromegalic patient during combined treatment with pegvisomant and octreotide long-acting repeatable attributed to the use of pegvisomant«. European Journal of Endocrinology. 154 (6): 805–6. doi:10.1530/eje.1.02160. PMID 16728538.
Moore DJ, Adi Y, Connock MJ, Bayliss S (Oktober 2009). »Clinical effectiveness and cost-effectiveness of pegvisomant for the treatment of acromegaly: a systematic review and economic evaluation«. BMC Endocrine Disorders. 9: 20. doi:10.1186/1472-6823-9-20. PMC 2768727. PMID 19814797.
Evans A, Jamieson SM, Liu DX, Wilson WR, Perry JK (Avgust 2016). »Growth hormone receptor antagonism suppresses tumour regrowth after radiotherapy in an endometrial cancer xenograft model«. Cancer Letters. 379 (1): 117–23. doi:10.1016/j.canlet.2016.05.031. PMID 27241667.
Divisova J, Kuiatse I, Lazard Z, Weiss H, Vreeland F, Hadsell DL, in sod. (Avgust 2006). »The growth hormone receptor antagonist pegvisomant blocks both mammary gland development and MCF-7 breast cancer xenograft growth«. Breast Cancer Research and Treatment. 98 (3): 315–27. doi:10.1007/s10549-006-9168-1. PMID 16541323. S2CID 6234700.

europa.eu

ema.europa.eu

Scientific Discussion of Somavert (PDF) (poročilo). Evropska agencija za zdravila. 2004. Arhivirano iz prvotnega spletišča (PDF) dne 18. junija 2018. Pridobljeno 21. junija 2021.

nih.gov

pubmed.ncbi.nlm.nih.gov

Schreiber I, Buchfelder M, Droste M, Forssmann K, Mann K, Saller B, Strasburger CJ (Januar 2007). »Treatment of acromegaly with the GH receptor antagonist pegvisomant in clinical practice: safety and efficacy evaluation from the German Pegvisomant Observational Study«. European Journal of Endocrinology. 156 (1): 75–82. doi:10.1530/eje.1.02312. PMID 17218728.
Rix, M.; Laurberg, P.; Hoejberg, A. S.; Brock-Jacobsen, B. (Avgust 2005). »Pegvisomant therapy in pituitary gigantism: successful treatment in a 12-year-old girl«. European Journal of Endocrinology. Zv. 153, št. 2. str. 195–201. doi:10.1530/eje.1.01956. ISSN 0804-4643. PMID 16061823.
Müssig, K.; Gallwitz, B.; Honegger, J.; Strasburger, C. J.; Bidlingmaier, M.; Machicao, F.; Bornemann, A.; Ranke, M. B.; Häring, H.-U. (Marec 2007). »Pegvisomant treatment in gigantism caused by a growth hormone-secreting giant pituitary adenoma«. Experimental and Clinical Endocrinology & Diabetes: Official Journal, German Society of Endocrinology [and] German Diabetes Association. Zv. 115, št. 3. str. 198–202. doi:10.1055/s-2007-956172. ISSN 0947-7349. PMID 17427111.
Freda PU, Gordon MB, Kelepouris N, Jonsson P, Koltowska-Haggstrom M, van der Lely AJ (Marec 2015). »Long-term treatment with pegvisomant as monotherapy in patients with acromegaly: experience from ACROSTUDY«. Endocrine Practice. 21 (3): 264–74. doi:10.4158/EP14330.OR. PMC 4618502. PMID 25370326.
Kopchick JJ (april 2003). »Discovery and mechanism of action of pegvisomant«. European Journal of Endocrinology. 148 Suppl 2: S21-5. doi:10.1530/eje.0.148s021. PMID 12670297.{{navedi časopis}}: Vzdrževanje CS1: samodejni prevod datuma (povezava)
Berryman DE, Palmer AJ, Gosney ES, Swaminathan S, DeSantis D, Kopchick JJ (2007). »Discovery and uses of pegvisomant: a growth hormone antagonist«. Endokrynologia Polska. 58 (4): 322–9. PMID 18058724.
Neggers SJ, Muhammad A, van der Lely AJ (2015). »Pegvisomant Treatment in Acromegaly«. Neuroendocrinology. 103 (1): 59–65. doi:10.1159/000381644. PMID 25792221. S2CID 19588354.
Feenstra J, van Aken MO, de Herder WW, Feelders RA, van der Lely AJ (Junij 2006). »Drug-induced hepatitis in an acromegalic patient during combined treatment with pegvisomant and octreotide long-acting repeatable attributed to the use of pegvisomant«. European Journal of Endocrinology. 154 (6): 805–6. doi:10.1530/eje.1.02160. PMID 16728538.
Moore DJ, Adi Y, Connock MJ, Bayliss S (Oktober 2009). »Clinical effectiveness and cost-effectiveness of pegvisomant for the treatment of acromegaly: a systematic review and economic evaluation«. BMC Endocrine Disorders. 9: 20. doi:10.1186/1472-6823-9-20. PMC 2768727. PMID 19814797.
Evans A, Jamieson SM, Liu DX, Wilson WR, Perry JK (Avgust 2016). »Growth hormone receptor antagonism suppresses tumour regrowth after radiotherapy in an endometrial cancer xenograft model«. Cancer Letters. 379 (1): 117–23. doi:10.1016/j.canlet.2016.05.031. PMID 27241667.
Divisova J, Kuiatse I, Lazard Z, Weiss H, Vreeland F, Hadsell DL, in sod. (Avgust 2006). »The growth hormone receptor antagonist pegvisomant blocks both mammary gland development and MCF-7 breast cancer xenograft growth«. Breast Cancer Research and Treatment. 98 (3): 315–27. doi:10.1007/s10549-006-9168-1. PMID 16541323. S2CID 6234700.

ncbi.nlm.nih.gov

Freda PU, Gordon MB, Kelepouris N, Jonsson P, Koltowska-Haggstrom M, van der Lely AJ (Marec 2015). »Long-term treatment with pegvisomant as monotherapy in patients with acromegaly: experience from ACROSTUDY«. Endocrine Practice. 21 (3): 264–74. doi:10.4158/EP14330.OR. PMC 4618502. PMID 25370326.
Moore DJ, Adi Y, Connock MJ, Bayliss S (Oktober 2009). »Clinical effectiveness and cost-effectiveness of pegvisomant for the treatment of acromegaly: a systematic review and economic evaluation«. BMC Endocrine Disorders. 9: 20. doi:10.1186/1472-6823-9-20. PMC 2768727. PMID 19814797.

ohio.edu

»Ohio University, inventors to receive up to $52 million from drug license transactions«. Ohio University. 15. februar 2011. Arhivirano iz prvotnega spletišča dne 22. novembra 2016. Pridobljeno 21. junija 2021.

semanticscholar.org

api.semanticscholar.org

Neggers SJ, Muhammad A, van der Lely AJ (2015). »Pegvisomant Treatment in Acromegaly«. Neuroendocrinology. 103 (1): 59–65. doi:10.1159/000381644. PMID 25792221. S2CID 19588354.
Divisova J, Kuiatse I, Lazard Z, Weiss H, Vreeland F, Hadsell DL, in sod. (Avgust 2006). »The growth hormone receptor antagonist pegvisomant blocks both mammary gland development and MCF-7 breast cancer xenograft growth«. Breast Cancer Research and Treatment. 98 (3): 315–27. doi:10.1007/s10549-006-9168-1. PMID 16541323. S2CID 6234700.

termania.net

»Termania - Slovenski medicinski slovar - somatotropín«. www.termania.net. Pridobljeno 21. junija 2021.

web.archive.org

Scientific Discussion of Somavert (PDF) (poročilo). Evropska agencija za zdravila. 2004. Arhivirano iz prvotnega spletišča (PDF) dne 18. junija 2018. Pridobljeno 21. junija 2021.
»Ohio University, inventors to receive up to $52 million from drug license transactions«. Ohio University. 15. februar 2011. Arhivirano iz prvotnega spletišča dne 22. novembra 2016. Pridobljeno 21. junija 2021.
CEDAC Final REcommendation on Reconsideration and Reasons for Recommendation: Pegvisomant (Somavert - Pfizer Canada Inc.) (PDF) (poročilo). Canadian Agency for Drugs and Technologies in Health. 2. avgust 2006. Arhivirano iz prvotnega spletišča (PDF) dne 28. junija 2021. Pridobljeno 21. junija 2021.

worldcat.org

Rix, M.; Laurberg, P.; Hoejberg, A. S.; Brock-Jacobsen, B. (Avgust 2005). »Pegvisomant therapy in pituitary gigantism: successful treatment in a 12-year-old girl«. European Journal of Endocrinology. Zv. 153, št. 2. str. 195–201. doi:10.1530/eje.1.01956. ISSN 0804-4643. PMID 16061823.
Müssig, K.; Gallwitz, B.; Honegger, J.; Strasburger, C. J.; Bidlingmaier, M.; Machicao, F.; Bornemann, A.; Ranke, M. B.; Häring, H.-U. (Marec 2007). »Pegvisomant treatment in gigantism caused by a growth hormone-secreting giant pituitary adenoma«. Experimental and Clinical Endocrinology & Diabetes: Official Journal, German Society of Endocrinology [and] German Diabetes Association. Zv. 115, št. 3. str. 198–202. doi:10.1055/s-2007-956172. ISSN 0947-7349. PMID 17427111.